UNSPSC 51162019: Dyphylline/ephedrine/guaifenesin/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162019 Dyphylline/ephedrine/guaifenesin/phenobarbital is a Commodity code that in recent state and local solicitations does not reflect actual purchasing activity for the branded pharmaceutical combination it nominally names. Instead, the code is being applied to a broad range of pharmaceutical procurement including naloxone emergency-response systems, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. The actual work being solicited under this code encompasses vendor selection for emergency medical supplies (naloxone), contracted pharmacy benefit management and dispensing services at government health clinics, and supply agreements for generic medications across multi-state cooperative purchasing vehicles. Issuing bodies include county health departments (Seminole County, Florida; Hall County, Georgia), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government facilities including Oregon). The code shows little coherence with its nominal scope; recent opportunities do not target the specific combination therapeutic product the code names.

Recent activity spans Florida, Georgia, Texas, and Minnesota/multi-state cooperative membership, indicating geographic distribution across multiple regions without concentration in a single state. Representative recent opportunities include Seminole County, Florida issuing IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023; Hall County, Georgia issuing RFQ/P #47-010 for on-site pharmacy services at its Family Health Center Clinic in Gainesville to serve approximately 3,005 eligible individuals, with sealed proposals due June 4, 2026; the Texas HHS Commission issuing RFI HHS0017013 on April 3, 2026 to solicit vendor capabilities for direct-to-manufacturer prescription programs; and Minnesota Multistate Cooperative Purchasing Alliance issuing an RFP for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, for a July 1, 2026 effective date. The mismatch between the code's nominal pharmaceutical product and the actual scope of recent procurement (emergency response systems, clinic-based dispensing, bulk generic supply) suggests the code is being used as a catch-all classification for pharmacy-related government purchasing rather than targeting the specific combination drug product the code nominally describes.